Benzinga | Sep 7, 2021 08:23AM EDT

New Data at IASLC 2021 World Conference On Lung Cancer Demonstrates Advantages Of Using the Guardant360 Liquid Biopsy Blood Test For Comprehensive Genomic Profiling In Advanced Lung Cancer

Guardant Health, Inc. (NASDAQ:GH) along with leading academic institutions and pharmaceutical companies will present data demonstrating the advantages of using the Guardant360(r) liquid biopsy test for clinical decision-making in advanced lung cancer at the IASLC 2021 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, September 8-14, 2021.

"The new data adds further to the body of evidence illustrating the benefits of using the Guardant360(r) liquid biopsy test to easily and quickly identify more patients with actionable biomarkers," said Helmy Eltoukhy, Guardant Health co-CEO. "Clinicians are able to start biomarker informed treatment sooner by using our blood test compared to using a tissue biopsy for comprehensive genomic profiling."

Guardant360(r) Liquid Biopsy Delivers Comprehensive Results with Fast Turn-Around Time for Clinical Decision-Making

Title Abstract Date No. OralThe Economic Value of Liquid Biopsy for Genomic OA16.02 presentation:Profiling in Advanced Non-Small Cell Lung Cancer September 12, 2021Plasma NGS At Time of Diagnostic Tissue Biopsy ? OralImpact on Time to Treatment: Results From a Pilot OA16.01 presentation:Prospective Study September 12, 2021Using Liquid Biopsy to Guide First-Line Therapy ePoster:Decisions in Patients With Metastatic Non-Small Cell P24.05 September 8,Lung Cancer 2021Stacking on the Targets: Secondary Resistant, ePoster:Potential Targetable Genetic Alterations in Patients P51.02 September 8,with Epidermal Growth Factor Receptor NSCLC 2021Real-World Concordance Between Tumor Mutational ePoster:Burden From Blood and Tissue in Lung Cancer and Other P21.02 September 8,Cancers 2021

Guardant360 CDx is Highly Concordant and Delivers Comparable Overall Response Rate (ORR) Compared to Tissue Based Comprehensive Genomic Profiling for Amivantamab

Title Abstract Date No.Validation of Companion Diagnostics for the Identification ePoster:of Patients with EGFR Exon20ins NSCLC for Amivantamab P24.14 SeptemberTherapy 8, 2021